



Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and	
Name of listed issuer:	Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:	7-Jun-17
Date of last disclosure:	23-Sep-16

Director or senior manager giving disclosure

Full name(s):	Paul Nigel SHEARER
Name of listed issuer:	Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):	
Position held in listed issuer:	Senior Vice President - Sales & Marketing

Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

Class of affected quoted financial products:	Ordinary Shares
Nature of the affected relevant interest(s):	Beneficial Interest in Ordinary Shares
For that relevant interest-	
Number held in class before acquisition or disposal:	(a) 129,641 Ordinary Shares (b) 330,178 Options to acquire Ordinary Shares
Number held in class after acquisition or disposal:	(a) 143,580 Ordinary Shares (b) 264,178 Options to acquire Ordinary Shares
Current registered holder(s):	Paul Nigel SHEARER
Registered holder(s) once transfers are registered:	Paul Nigel SHEARER

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

Type of affected derivative:	Not Applicable
Class of underlying financial products:	
Details of affected derivative-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	

Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates:	Two
Details of transactions requiring disclosure-	
Date of transaction:	(a) 30 May 2017 (b) 31 May 2017
Nature of transaction:	(a) Sale of 30,000 Ordinary Shares (b) Exercise of 66,000 Options and issue of 43,939 Ordinary Shares
Name of any other party or parties to the transaction (if known):	
The consideration, expressed in New Zealand dollars, paid or recieved for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	(a) NZ\$320,010.58 (b) NZ\$469,286.40
Number of financial products to which the transaction related: <i>If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—</i>	(a) 30,000 Ordinary Shares (b) 43,939 Ordinary Shares
Whether relevant interests were aquired or disposed of during a closed period:	No
Whether prior written clearance was provided to allow the aquisition or disposal to proceed during the closed period:	Not Applicable
Date of the prior written clearance (if any):	Not Applicable

Summary of other relevant interests after acquisition or disposal:

Class of quoted financial products:	(a) Shares in Trust under Employee Share Scheme (b) Performance Share Rights over Ordinary Shares (c) Shares in Family Trust
Nature of relevant interest:	Beneficial
<i>For that relevant interest,-</i>	
Number held in class:	(a) 410 Shares in Trust under Employee Share Scheme (b) 70,539 Performance Share Rights over Ordinary Shares (c) 275,772 Ordinary Shares
Current registered holder(s):	Paul Nigel SHEARER
<i>For a derivative relevant interest,-</i>	
Type of derivative:	
Details of derivative,-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price's specified terms (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
<i>For that derivative relevant interest,-</i>	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	

Cerification

I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.	
Signature of director or officer:	
Date of signature:	
or	
Signature of person authorised to sign on behalf of director or officer:	
Date of signature:	7-Jun-17
Name and title of authorised person:	

Notes